Cargando…
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models
BACKGROUND: Although the epidermal growth factor receptor (EGFR) is a frequent oncogenic driver in glioblastoma (GBM), efforts to therapeutically target this protein have been largely unsuccessful. The present preclinical study evaluated the novel EGFR inhibitor WSD-0922. METHODS: We employed flank...
Autores principales: | Conage-Pough, Jason E, Stopka, Sylwia A, Oh, Ju-Hee, Mladek, Ann C, Burgenske, Danielle M, Regan, Michael S, Baquer, Gerard, Decker, Paul A, Carlson, Brett L, Bakken, Katrina K, Zhang, Jinqiang, Liu, Lily, Sun, Claire, Mu, Zhihua, Zhong, Wei, Tran, Nhan L, Elmquist, William F, Agar, Nathalie Y R, Sarkaria, Jann N, White, Forest M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263119/ https://www.ncbi.nlm.nih.gov/pubmed/37324218 http://dx.doi.org/10.1093/noajnl/vdad066 |
Ejemplares similares
-
TIPS-09 FIRST-IN-HUMAN PHASE 1 TRIAL OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF WSD0922-FU (NCT04197934): TRIAL IN PROGRESS
por: Kizilbash, Sani, et al.
Publicado: (2023) -
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts
por: Porath, Kendra A, et al.
Publicado: (2022) -
Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks
por: Kohale, Ishwar N., et al.
Publicado: (2021) -
Quantitative Consequences of Protein Carriers in Immunopeptidomics and Tyrosine Phosphorylation MS(2) Analyses
por: Stopfer, Lauren E., et al.
Publicado: (2021) -
Genome-wide analysis of the WSD family in sunflower and functional identification of HaWSD9 involvement in wax ester biosynthesis and osmotic stress
por: Zhang, Cheng, et al.
Publicado: (2022)